IE
CLDI icon

Israel Englander’s Calidi Biotherapeutics CLDI Stock Holding History

Israel Englander’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-709
Closed -$157K – 5918
2024
Q4 		$157K Buy
+709
New +$213K ﹤0.01% 5382
2024
Q1 		– Sell
-53
Closed -$154K – 6227
2023
Q4 		$154K Buy
+53
New +$228K ﹤0.01% 5241
2022
Q3 		– Sell
-545
Closed -$10.4M – 7101
2022
Q2 		$10.4M Buy
545
+287
+111% +$5.47M 0.01% 1982
2022
Q1 		$4.89M Buy
+258
New +$4.88M ﹤0.01% 2961

Other funds holding CLDI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

Israel Englander's CLDI Position: Q1 2025 in Review

Israel Englander sold out of Calidi Biotherapeutics (CLDI) in Q1 2025, closing a stake of 709 shares — an estimated $157K sold.

Israel Englander first reported a position in CLDI in Q1 2022 and held it in 4 quarters. The position peaked at $10.4M in Q2 2022. 35 funds tracked by Wall St. Rank hold CLDI as of Q1 2025.

  • Israel Englander reported no remaining Calidi Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Israel Englander sold 709 Calidi Biotherapeutics shares in Q1 2025, an estimated $157K.
  • Israel Englander first reported a position in Calidi Biotherapeutics in Q1 2022 and held it in 4 quarters.
  • Israel Englander's Calidi Biotherapeutics position peaked at $10.4M in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.